We're tackling cancer with a new approach by identifying disease-specific, pathologic conformers, and targeting the most efficacious epitopes on those targets.
We're tackling cancer with a new approach by identifying disease-specific, pathologic conformers, and targeting the most efficacious epitopes on those targets.